SEC
INSY

Seven Eight Capital’s Insys Therapeutics, Inc. INSY Stock Holding History

Seven Eight Capital’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,475
Closed -$99K – 732
2015
Q4 		$99K Buy
+3,475
New +$96.3K 0.07% 346

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Seven Eight Capital's INSY Position: Q1 2016 in Review

Seven Eight Capital sold out of Insys Therapeutics, Inc. (INSY) in Q1 2016, closing a stake of 3,475 shares — an estimated $99K sold.

Seven Eight Capital first reported a position in INSY in Q4 2015 and held it in 1 quarter. The position peaked at $99K in Q4 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q1 2016.

  • Seven Eight Capital reported no remaining Insys Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Seven Eight Capital sold 3,475 Insys Therapeutics, Inc. shares in Q1 2016, an estimated $99K.
  • Seven Eight Capital first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Seven Eight Capital's Insys Therapeutics, Inc. position peaked at $99K in Q4 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2016.

Based on Seven Eight Capital's 13F filing for Q1 2016, filed 16 May 2016.